Policy Supported
Letters Supported & Letters Submitted
PRN and 25 Patient Groups Send Letter to Hill on Generic Drugs
Patients Rising Now, along with 25 other patient groups, sent a letter to Congressional leadership as well as Senate HELP committee and House E&C leadership urging support for generic drug policy riders. The 117th Congress will soon enter the final session period...
Patients Rising Now Sends Letter to House and Senate Leadership Encouraging Support for Home Healthcare Bill
Patients Rising Now and 12 other organizations sent a letter to the House of Representatives and Senate leadership encouraging support for the Preserving Access to Home Health Act of 2022 (H.R. 8581/S. 4605). There is currently a Centers for Medicare and Medicaid...
Patients Rising Now Signs onto CMS Letter Supporting Access to Chronic Kidney Disease Care
Patients Rising Now signed onto a letter to CMS Administrator Chiquita Brooks-LaSure calling for CMS to improve access to Chronic Kidney Disease (CKD) Treatment for Medicare beneficiaries. CKD and other kidney-related disorders are very common in both Americans aged...
PRN Signs onto Biomarker Bill Letter
Patients Rising Now signed onto a letter urging Governor Newsom of California to sign SB 912 into law as soon as possible. SB 912 would require private and public health plans to recognize and cover biomarker tests. The practice of biomarker testing is where a...
PRN Sends Letter about PBM Patient-Steering
Patients Rising Now sent a letter to the New York State Department of Financial Services about Pharmacy Benefit Managers. PBMs possess a considerable amount of leverage in the health space and use that leverage to steer patients to in-house or otherwise...
PRN Sends Letter to HHS Calling for Increased Patient Protection in Nuclear Medicine
Patients Rising Now sent a letter to the Office of the Inspector General department that oversees the Department of Health and Human Services. As part of our commitment to patient access, affordability, and safety, we are members of the Patients for Safer Nuclear...
Patients Rising Now Calls on Lawmakers to Create Federal Rare Disease Program
We sent a letter to members of the House and Senate Appropriations Committees regarding FY23 funding. The House bills that fund HHS and FDA both established double digit percentage increases in funding; we thanked House lawmakers for their continued support of these...
Patients Rising Now Sends Letter to NY Governor Hochul Urging Copay Accumulator Bill be Signed into Law
We sent a letter to New York Governor Kathy Hochul urging her not to delay in signing A1741-A into law. A1741-A passed in May of this year almost unanimously in the New York Assembly and Senate. The bill would prohibit copay accumulators and require that any...
Patients Rising Now Joins over 100 Associations on Pharmacy Benefit Managers Letter
Patients Rising Now signed onto a letter to the Federal Trade Commission (FTC) regarding Pharmacy Benefit Managers (PBMs) with 105 other associations. This was a letter we signed onto in addition to the comments we submitted on behalf of our own organization. The PBM...
Patients Rising Now Signs onto LEAD Coalition Letter Calling for Increased Alzheimer’s Research Funding
Patients Rising Now has signed onto the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's letter to the House and Senate Appropriations Committees calling for increased Alzheimer's research funding for Fiscal Year 2023. The letter calls for all health agencies...
Patients Rising Now Pens Letter in Support of Huntington’s Disease Legislation
Huntington's Disease is a rare, degenerative disease that leads to the breakdown of cells in the brain. For decades, patients who received that devastating diagnosis have had to undergo months, and even years, of waiting and maneuvering through red-tape before they...
Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021
We appreciate the work of the Senate Committee on Health, Education, Labor, and Pensions (HELP) in reauthorizing the Food and Drug Administration’s (FDA) user fee programs for generic drugs (GDUFA). The improvements in GDUFA III will speed patient access to safe,...